Table 2.
Bivariate Analysis of the Severity and Duration of Influenzalike Illness Symptoms Among Subjects With Cell Culture–Confirmed Influenza Infection
| No. (%) of Subjects With Symptoms |
|||||||
| Symptoms | Total | Mild | Moderate | Severe | Mean Severity Scorea | Duration, Days, Mean (Median) | P Valueb |
| VCIV (n = 21) | |||||||
| Pyrexia | 12 (57) | 5 (23.8) | 6 (28.6) | 1 (4.8) | 1.7 | 3.6 (3.0) | .491 |
| Cough | 15 (71) | 9 (42.9) | 6 (28.6) | 0 | 1.4 | 8.8 (7.0) | .143 |
| Oropharyngeal pain | 16 (76) | 10 (47.6) | 6 (28.6) | 0 | 1.4 | 7.4 (5.0) | .083 |
| Myalgia | 13 (62) | 8 (38.1) | 5 (23.8) | 0 | 1.4 | 4.2 (3.0) | .003 |
| Headache | 11 (52) | 9 (42.9) | 2 (9.5) | 0 | 1.2 | 5.6 (5.0) | .025 |
| Fatigue | 12 (57) | 8 (38.1) | 3 (14.3) | 1 (4.8) | 1.4 | 4.9 (3.5) | .013 |
| Nausea | 8 (38) | 5 (23.8) | 3 (14.3) | 0 | 1.4 | 6.9 (6.0) | .479 |
| Placebo (n = 74) | |||||||
| Pyrexia | 48 (65) | 26 (35.1) | 17 (23.0) | 5 (6.8) | 1.6 | 4.4 (3.5) | … |
| Cough | 63 (85) | 28 (37.8) | 30 (40.5) | 5 (6.8) | 1.6 | 10.0 (8.0) | … |
| Oropharyngeal pain | 43 (58) | 21 (28.4) | 19 (25.7) | 3 (4.1) | 1.6 | 8.1 (7.0) | … |
| Myalgia | 51 (69) | 20 (27.0) | 29 (39.2) | 2 (2.7) | 1.6 | 7.8 (7.0) | … |
| Headache | 45 (61) | 24 (32.4) | 17 (23.0) | 4 (5.4) | 1.6 | 7.1 (6.0) | … |
| Fatigue | 42 (57) | 19 (25.7) | 21 (28.4) | 2 (2.7) | 1.6 | 7.4 (6.0) | … |
| Nausea | 21 (28) | 11 (14.9) | 10 (13.5) | 0 | 1.5 | 5.1 (5.0) | … |
Abbreviations: ILI, influenzalike illness; VCIV, Vero cell culture–derived influenza vaccine.
a
Symptoms rated as mild were given a score of 1, moderate symptoms a score of 2, and severe symptoms a score of 3.
b
P value (POSET test) of the reduction in severity and duration of symptoms in VCIV recipients compared with placebo recipients.